circle

INVESTORS & MEDIA

PRESS RELEASES

Keyword Search

Press Release Archive
Date Title  
December 1, 2020
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
link
December 1, 2020
Cytokinetics Announces Additional Results From GALACTIC-HF to be Presented at the 17th Global Cardiovascular Clinical Trialists Forum
link
November 24, 2020
Cytokinetics to Participate in Upcoming Investor Conferences
link
November 23, 2020
Cytokinetics Regains Rights to Develop and Commercialize Omecamtiv Mecarbil and AMG 594 From Amgen
link
November 20, 2020
Cytokinetics Names Nancy Wysenski to Board of Directors
link
November 16, 2020
Cytokinetics Announces Preclinical Data for CK-3773274 and CK-3772271 Presented at the AHA Scientific Sessions 2020
link
November 16, 2020
Cytokinetics Announces Presentations Related to Health Economics and Outcomes Research in Heart Failure and Hypertrophic Cardiomyopathy at the AHA Scientific Sessions 2020
link
November 13, 2020
Cytokinetics Announces Results From GALACTIC-HF Presented at Late Breaking Clinical Trial Session at the American Heart Association Scientific Sessions and Published in the New England Journal of Medicine
link
November 10, 2020
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
link
November 6, 2020
Cytokinetics Announces Six Presentations Related to Heart Failure and Hypertrophic Cardiomyopathy at the AHA Scientific Sessions 2020
link
November 4, 2020
Cytokinetics Reports Third Quarter 2020 Financial Results
link
October 21, 2020
Cytokinetics to Announce Third Quarter Results on November 4, 2020
link
October 8, 2020
Amgen, Cytokinetics and Servier Announce Topline Results From GALACTIC-HF, a Phase 3 Trial of Omecamtiv Mecarbil in Patients With Heart Failure
link
October 5, 2020
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
link
October 5, 2020
Cytokinetics Announces Data From Two Presentations at the HFSA Virtual Annual Scientific Meeting 2020
link
October 2, 2020
Cytokinetics Announces Publication of Manuscript Detailing Baseline Characteristics of GALACTIC-HF in European Journal of Heart Failure
link
September 24, 2020
Cytokinetics Announces Data to Be Presented at the HFSA Virtual Annual Scientific Meeting 2020
link
September 24, 2020
Cytokinetics Announces Third Annual Communications Fellowship Program Call for Proposals
link
September 23, 2020
Cytokinetics Announces Initiation of Phase 1 Clinical Study of CK-3772271
link
September 17, 2020
Cytokinetics Announces GALACTIC-HF Accepted for Presentation In Late Breaking Clinical Trial Session At American Heart Association Scientific Sessions
link
September 2, 2020
Cytokinetics to Participate in Upcoming Investor Conferences
link
August 26, 2020
Cytokinetics and Cure SMA Renew Partnership to Advance Education and Awareness of SMA
link
August 18, 2020
Cytokinetics Announces Partnership to Improve Prediction of Risk and Outcomes in Hypertrophic Cardiomyopathy
link
August 6, 2020
Cytokinetics Reports Second Quarter 2020 Financial Results
link
July 23, 2020
Cytokinetics to Announce Second Quarter Results on August 6, 2020
link
July 21, 2020
Cytokinetics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
link
July 16, 2020
Cytokinetics Announces Pricing of Public Offering of Common Stock
link
July 15, 2020
Cytokinetics Announces Proposed Public Offering of Common Stock
link
July 15, 2020
Cytokinetics Provides Updates on Its Cardiovascular Pipeline and Strategies to Build a Commercial Franchise at Today’s Virtual Investor & Analyst Day
link
July 14, 2020
Cytokinetics Announces Licensing Collaboration and Royalty Monetization Deals with RTW Investments Focused to CK-3773274, Next-Generation Cardiac Myosin Inhibitor
link
July 13, 2020
Cytokinetics Announces Participation in the Launch of Kainomyx, Inc. Focused to the Treatment of Parasitic Diseases
link
July 1, 2020
Cytokinetics to Host Virtual Investor & Analyst Day on July 15, 2020
link
June 8, 2020
Cytokinetics to Participate In Upcoming Investor Conferences
link
May 27, 2020
Cytokinetics and The ALS Association Renew Partnership to Advance the Fight Against ALS
link
May 8, 2020
FDA Grants Fast Track Designation For Omecamtiv Mecarbil In Heart Failure
link
May 7, 2020
Cytokinetics to Hold Annual Meeting of Stockholders
link
May 6, 2020
Cytokinetics Reports First Quarter 2020 Financial Results
link
April 22, 2020
Cytokinetics to Announce First Quarter Results on May 6, 2020
link
April 14, 2020
Cytokinetics Provides Clinical Trials and Business Update in Response to COVID-19 Pandemic
link
April 8, 2020
Cytokinetics to Participate in the 19th Annual Needham Virtual Healthcare Conference
link
March 30, 2020
Correction: Cytokinetics Announces Baseline Characteristics from GALACTIC-HF at ACC.20/WCC Virtual
link
March 20, 2020
Cytokinetics to Announce Baseline Characteristics from GALACTIC-HF During ACC.20/WCC
link
March 4, 2020
Cytokinetics Granted European Orphan Designation for Reldesemtiv for the Treatment of Amyotrophic Lateral Sclerosis
link
March 3, 2020
Cytokinetics Reports Fourth Quarter 2019 Financial Results
link
March 3, 2020
Cytokinetics Announces Preclinical Data for AMG 594 Presented at the Keystone Symposium on Heart Failure
link
February 28, 2020
Cytokinetics Joins Global Initiative to Recognize International Rare Disease Day
link
February 26, 2020
Amgen, Cytokinetics And Servier Announce Continuation Of GALACTIC-HF Following Planned Interim Analysis
link
February 20, 2020
Cytokinetics Announces Preclinical Data for CK-3773274 Presented at the Biophysical Society 64th Annual Meeting
link
February 18, 2020
Cytokinetics to Announce Fourth Quarter Results on March 3, 2020
link
February 6, 2020
Cytokinetics Announces Publication Relating to Design of GALACTIC-HF, a Phase 3 Clinical Trial of Omecamtiv Mecarbil in Patients With Heart Failure
link
January 22, 2020
Cytokinetics Announces Recipients of Second Annual Communications Fellowship Grants
link
January 13, 2020
Cytokinetics Announces Vision 2025 and Outlines 2020 Corporate Milestones
link
January 6, 2020
Cytokinetics Announces Start of REDWOOD-HCM, a Phase 2 Clinical Trial of CK-3773274
link